Fig. 2
From: Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
a Differences in probability of dying in the pulmonology unit or being intubated during the follow-up in noninvasively ventilated patients treated and not treated with TCZ (log-rank p value = 0.036). b Differences in probability of dying in the pulmonology unit or being intubated between patients treated with IV or SC TCZ, or not treated with TCZ. The difference was significantly lower in patients treated with IV TCZ compared to those untreated (log-rank p value = 0.01), but not in patients treated with the SC formulation (log-rank p value = 0.45)